Long-acting interleukin-7 improves the efficacy of oncolytic viral therapy in glioblastoma - PubMed
4 days ago
- #immunotherapy
- #glioblastoma
- #oncolytic virus
- Long-acting interleukin-7 (rhIL-7-hyFc) enhances oncolytic viral therapy efficacy in glioblastoma (GBM).
- The 'expand and pull' strategy increases peripheral T cell abundance and recruits them to the tumor microenvironment.
- Combining rhIL-7-hyFc with Zika virus (ZIKV) improves T cell function and delays inhibitory checkpoint receptor expression.
- Similar efficacy observed with genetically modified Δ10 3'-UTR ZIKV and oncolytic adenovirus Delta24-RGD.
- Augmenting systemic and local immune responses enhances GBM-targeted immunotherapies.